Lexeo Therapeutics, based in New York City, received FDA breakthrough therapy designation for LX2006, its drug candidate targeting Friedreich’s ataxia (FA) cardiomyopathy—a leading cause of death in FA patients. The designation aims to expedite development based on promising early clinical data from SUNRISE-FA and CLARITY-FA trials.
LX2006 delivers a functional frataxin gene to restore mitochondrial function, addressing an unmet need with no current cure. The candidate also benefits from FDA’s fast track and Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) designations.
Sandi See Tai, Lexeo’s Chief Development Officer, highlighted the encouraging impact on cardiac and broader FA functional measures and emphasized ongoing FDA collaboration.
Follow MEDWIRE.AI for updates on breakthrough cardiovascular therapies.
